-
A report in the July 29 issue of Circulation, the journal of the American Heart Association (AHA; Dallas, Texas), says that prevention and education efforts must be pursued to curb the growing trend of hospitalizations for atrial fibrillation (AF) in the U.S.
-
AmeriNet (St. Louis, Missouri), a healthcare group purchasing organization, has renewed its immuno- assay agreement with Beckman Coulter (Fullerton, California). The three-year contract is valued at $60 million. The renewal includes pricing agreements for Beckman Coulters entire line of immunoassay systems, test kits, supplies and services.
-
In a webcast conference call last month, replacement heart manufacturer Abiomed (Danvers, Massachusetts) provided a sketchy overview of its current activities, with that overview tending to underline at least two critical points for the company:
-
A Canadian physician has developed a device that could replace drug-eluting stents in preventing restenosis or re-narrowing of coronary arteries and help to heal diseased arteries. The first implantation of an antibody-coated stent on a human was performed in May at the Thoraxcentre of the University Hospital Rotterdam (Rotterdam, the Netherlands).
-
-
If youre not in full compliance with the National Safety Patient Goals for 2004 from the Oakbrook Terrace, IL-based Joint Commission on Accreditation of Healthcare Organizations, you have a lot to worry about.
-
If your facility isnt a Level 1 Trauma Center, you probably dont care for trauma patients with multiple injuries on a daily basis.
-
Here are the steps taken when a patient with suspected deep venous thrombosis (DVT) presents at Seattle-based Harborview Medical Centers ED, according to Cynthia Natiello, RNC BSN, CCRC, the facilitys vascular research nurse:
-
A 90-year-old woman complains of leg pain and swelling, with a history of hormone replacement therapy use, hypertension, osteoarthritis, and recent eye surgery.
-